Strain Data Sheet
RBRC00916
Information1 | |
|---|---|
| Image |  |
| BRC No. | RBRC00916 |
| Type | Targeted Mutation |
| Species | Mus musculus |
| Strain name | B6.Cg-Irf9<tm1Ttg>/TtgRbrc |
| Former Common name | IRF-9 KO/C57BL/6J ; p48<-/->; IRF-9<-/->, IRF-9 Knockout mouse, C57BL/6J |
| H-2 Haplotype | |
| ES Cell line | TT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1] |
| Background strain | C57BL/6JJcl |
| Appearance | black |
| Strain development | Developed by Tadatsugu Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo. RBRC00915: Backcrossed to BALB/c (N8 generations), RBRC00916: Backcrossed to C57BL/6J (over N13 generations). |
| Strain description | IRF-9 gene knockout mice. Homozygous mutant mice exhibit lower serum interferon levels in response to viral infection. BALB/c background (RBRC00915), C57BL/6 background (RBRC00916). |
| Colony maintenance | Homozygote x Homozygote |
| References | Genes Cells, 1, 115-124 (1996). 9078371 |
Health Report | |
|---|---|
| Examination Date / Room / Rack | |
Gene | |
|---|---|
| Gene info | Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter Irf9interferon regulatory factor 914Irf9<tm1Ttg>targeted mutation 1, Tadatsugu TaniguchiIrf-9, p48, Isgf3g Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter neoneomycin resistance gene (E. coli)14neo; neomycin;mouse phosphoglycerate kinase promoter (PGK promoter) |
Information2 | |
|---|---|
| Donor DNA | mouse phosphoglycerate kinase promoter (PGK promoter), E. coli neo, mouse IRF-9 genomic DNA |
| Research application | Immunology and Inflammation Research |
| Specific Term and Conditions | The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE. |
| Depositor | Tadatsugu Taniguchi (The University of Tokyo) |
| Strain Status |  Frozen embryos |
| Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) Cryopreserved embryos (within 1 month) |
| Additional Info. | Genetic Background Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
|---|
Hofer MJ, Li W, Lim SL, Campbell IL. The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9. J Neurosci 30(3) 1149-57(2010) 20089923 Li W, Hofer MJ, Jung SR, Lim SL, Campbell IL. IRF7-dependent type I interferon production induces lethal immune-mediated disease in STAT1 knockout mice infected with lymphocytic choriomeningitis virus. J Virol 88(13) 7578-88(2014) 24760883 Hofer MJ, Li W, Manders P, Terry R, Lim SL, King NJ, Campbell IL. Mice deficient in STAT1 but not STAT2 or IRF9 develop a lethal CD4+ T-cell-mediated disease following infection with lymphocytic choriomeningitis virus. J Virol 86(12) 6932-46(2012) 22496215 Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, Narushima S, Vlamakis H, Motoo I, Sugita K, Shiota A, Takeshita K, Yasuma-Mitobe K, Riethmacher D, Kaisho T, Norman JM, Mucida D, Suematsu M, Yaguchi T, Bucci V, Inoue T, Kawakami Y, Olle B, Roberts B, Hattori M, Xavier RJ, Atarashi K, Honda K. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565(7741) 600-605(2019) 30675064 |